Century Therapeutics

Century Therapeutics PEG

The PEG Ratio (Price/Earnings-to-Growth) of Century Therapeutics (IPSC) as of Nov 17, 2026 is -0.17. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was -0.04 — a change of 341.06% (lower).

PEG

-0.17

YoY

341.06%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Century Therapeutics is 2025 -0.17 . PEG Ratio (Price/Earnings-to-Growth) of Century Therapeutics was 2024 -0.04 . It decreases by 341.06% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Century Therapeutics Stock analysis

What does Century Therapeutics do? Century Therapeutics develops off-the-shelf cell therapies for cancer treatment, focusing on allogeneic approaches using induced pluripotent stem cells (iPSCs). The company's platform enables the creation of immune effector cells from iPSCs, incorporating CRISPR technology for gene editing. Product candidates include CNTY-101 targeting CD19 for B-cell lymphoma, CNTY-102 targeting CD19 and CD22 for relapsed B-cell malignancies, CNTY-107 for Nectin-4-expressing solid tumors, and CNTY-104 as a multi-specific collaboration program for acute myeloid leukemia. The firm aims to address unmet medical needs in solid tumors and hematological malignancies. Century Therapeutics generates revenue through the development and commercialization of its cell therapy products. The company's pipeline targets high-need cancer indications, with CNTY-101 and CNTY-102 focused on blood cancers and CNTY-107 targeting solid tumors. CNTY-104 is developed through a collaboration, indicating potential revenue from partnership agreements. The firm's technology platform supports multiple product candidates, allowing for diversified revenue streams from different therapeutic areas. The primary customers for Century Therapeutics' products are healthcare providers treating cancer patients, particularly in hematology and oncology departments. The company targets unmet medical needs in relapsed, refractory B-cell lymphoma, solid tumors, and acute myeloid leukemia. Its focus on allogeneic therapies positions it to serve patients requiring off-the-shelf treatments rather than personalized cell therapies. The company's product portfolio addresses specific molecular targets like CD19, CD22, and Nectin-4, aligning with current treatment paradigms in oncology. Century Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Century Therapeutics stock

PEG Ratio (Price/Earnings-to-Growth) of Century Therapeutics is -0.17 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Century Therapeutics changed from -0.04 to -0.17, representing a 341.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Century Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Century Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Century Therapeutics

All Key Metrics — Century Therapeutics